UGT1A1 and neutropenia: Clinically, patients with either heterozygous UGT1A1*1/*28 or homozygous UGT1A1*28/*28 genotypes are more prone to severe irinotecan-associated toxicity, notably grade 3–4 neutropenia and/or diarrhea [15].